TOKYO, November 21, 2018 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the following organizational and personnel changes, effective January 1, 2019.

[Details of Organizational Changes]

1) Reorganization of Research & Development functions (Research Div., Translational Clinical Research (TCR) Div.)

Research and Development functions will be reorganized in order for in-house projects to proceed seamlessly from non-clinical phase to clinical development phase and to obtain Proof of Concept* (PoC) promptly.

<Overview>

In order to strengthen the bridging role between non-clinical and clinical, which is the original function of Translational Research, and execute seamless project transition from non-clinical stage to clinical stage, pharmacokinetics/metabolism and safety function of non-clinical development will be transferred to TR Div., and Development ADMET Dept. will be newly established. Research Div. will continue to manage discovery research as the main mission, however, project management will be conducted by integrated system with TR Div. In order to proceed pharmacokinetics/metabolism and safety evaluation at the drug discovery stage more efficiently, the company integrates both functions and establish Discovery ADMET Dept.

*Proof of Concept (Demonstration that the therapeutic effects conceived in the research stage is effective in clinical setting)
**ADMET: Absorption, Distribution, Metabolism, Excretion, and Toxicity

2) Change of the name of Customer Relationship Management Dept. (Marketing & Sales Div.)

Customer Relationship Management Dept. will be renamed Customer Solution Dept.

<Overview>

The department will be renamed to reflect its function to provide new solutions in collaboration by Marketing & Sales Div., Medical Affairs Div., and Drug Safety Div.

[Details of Personnel Changes]

Vice President

Please see the PDF file about other personnel changes.